Drug Database
ER

eribulin mesilate (Ailelin)

✓ Approved

Sino Biopharmaceutical Co., Ltd · 小分子 · 小分子

什么是 eribulin mesilate?

eribulin mesilate 是一种小分子,由Sino Biopharmaceutical Co., Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Ailelin
公司Sino Biopharmaceutical Co., Ltd
药物类别小分子
给药途径Injectable (Others)
状态Approved

治疗适应症

eribulin mesilate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

相关研究文献

PubMedASN neuro2026-11-17

TUBB2A as a Candidate Therapeutic Target for Alzheimer's Disease: Orotidine-Mediated Metabolic Mechanisms and Druggability.

Liang Liling L, Zhang Jingjing J, Zhang Ying Y

As the most prevalent neurodegenerative disorder, Alzheimer's disease (AD) poses a pressing need for novel therapeutic targets. This study was designed to address this gap by screening and validating druggable genetic targets nominally associated with AD through an integrative multi-omics approach. Mendelian randomization (MR) screened the druggable genome. GTEx eQTL data and differential expression analysis identified core candidates. SMR, GSMR, and cross-tissue eQTL validation assessed putative causal effects and cross-tissue generalizability. Single-cell RNA sequencing (scRNA-seq) dissected cell type-specific expression. Virtual knockout combined with cell-cell communication analysis elucidated regulatory mechanisms. Mediation analysis evaluated Cerebrospinal fluid (CSF) metabolite involvement, and molecular docking screened therapeutic agents. Genetically predicted TUBB2A expression was nominally associated with AD risk. Virtual knockout analysis revealed that TUBB2A deficiency induced significant upregulation of SLC1A3 and HIF3A, suggesting compensatory glutamate clearance and hypoxic stress responses. Nominal mediation analysis suggested that the CSF metabolite orotidine may be involved in the TUBB2A-AD association. Molecular docking revealed high binding affinity between Eribulin mesylate and TUBB2A. This study identifies TUBB2A as a priority candidate gene for further validation in AD, proposes a potential role for orotidine in TUBB2A-related AD susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies. susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies.

PMID 43042626
阅读全文 →
PubMedCase reports in women's health2026-11-16

Live birth after uterus-sparing management of disseminated intravascular coagulation following uterine evacuation for miscarriage in a woman with adenomyosis: a case report.

Akutsu Mariko M, Itagaki Hiroya H, Ino Yoshihiko Y, Tenjimbayashi Yuri Y et al.

Disseminated intravascular coagulation is a rare complication of miscarriage management in women with adenomyosis, and reproductive outcomes after uterine preservation have not been sufficiently documented. A 32-year-old woman diagnosed with adenomyosis by magnetic resonance imaging conceived after fresh embryo transfer. Five days after uterine evacuation by manual vacuum aspiration for a missed miscarriage at 10 weeks of gestation, she developed abdominal pain, vaginal bleeding, and overt disseminated intravascular coagulation. Acute treatment included blood component transfusion, antithrombin concentrate, gabexate mesilate, and empirical antibiotics. Uterus-sparing management was continued because her hemodynamic status stabilized, major bleeding did not persist, and coagulation parameters improved rapidly. Follow-up magnetic resonance imaging showed no evidence of extensive uterine necrosis. After four cycles of gonadotropin-releasing hormone agonist therapy, she conceived following frozen-thawed embryo transfer and delivered a live infant at term. Although transfusion was required for postpartum hemorrhage, there was no clinical recurrence of disseminated intravascular coagulation. This case suggests that uterine preservation may be feasible when bleeding is controlled and clinical and laboratory findings improve rapidly. However, surgery should not be delayed when bleeding, hemodynamic instability, worsening coagulopathy, or progressive uterine injury persists.

PMID 43036822
阅读全文 →
PubMedOncology letters2026-11-13

Durable response to eribulin in metastatic primary ovarian leiomyosarcoma: A case report.

Ninomiya Akitsu A, Kurita Tomoko T, Ishibashi Saki S, Kajio Haruka H et al.

Primary ovarian leiomyosarcoma is an exceptionally rare malignancy that accounts for <0.1% of ovarian cancers; however, evidence regarding effective systemic therapy for advanced disease remains limited. Treatment strategies are generally extrapolated from uterine leiomyosarcoma or soft tissue sarcoma regimens; however, therapeutic outcomes are inconsistent. The current report describes the case of a 77-year-old female patient with International Federation of Gynecology and Obstetrics stage IVB primary ovarian leiomyosarcoma who presented with liver and humeral metastases. Following surgery, the patient underwent three cycles of combination therapy with docetaxel and gemcitabine, but the disease progressed. The patient discontinued treatment with pazopanib due to grade 3 dermatologic toxicity. Eribulin treatment was initiated because anthracyclines were contraindicated due to cardiac dysfunction. After seven cycles, the humeral metastases completely resolved, and the liver metastases remained stable, thereby achieving a partial response. Disease control was maintained for ~10 months without significant adverse events, with preservation of quality of life. After the 13th cycle, new hepatic and pulmonary metastases developed and comprehensive genomic profiling revealed no actionable alterations. To the best of our knowledge, the present report is the first to demonstrate clinically meaningful and durable disease control using eribulin in advanced primary ovarian leiomyosarcoma.

PMID 43022126
阅读全文 →
PubMedThe American journal of case reports2026-11-11

Primary Synovial Sarcoma of the Thyroid Gland Presenting With Early Pulmonary Metastasis: Diagnostic Pathway, SS18 Gene Fusion Confirmation, and Clinical Course.

Edwards Andrew G AG, Petroski Jack J, Patel Raj R, Koyfman Sergey S

BACKGROUND Primary synovial sarcoma of the thyroid gland (PSST) is an exceptionally rare and aggressive neoplasm. Twenty-one cases have been reported in the literature to date, making this the 22nd reported occurrence. This report presents the case of a 47-year-old woman with PSST confirmed by SS18 gene fusion on fluorescence in situ hybridization (FISH), who subsequently developed pulmonary metastasis and doxorubicin-induced congestive heart failure, illustrating the aggressive clinical course of this entity. CASE REPORT We report the case of a 47-year-old woman presenting with dysphagia and a left-sided neck mass. Initial FNA was non-diagnostic; repeat FNA raised concern for a spindle cell neoplasm. Left hemithyroidectomy was performed with negative margins, and SS18 gene fusion was confirmed by FISH, establishing the diagnosis of PSST. Following multidisciplinary review, adjuvant chemotherapy was deferred and neck radiation was administered. Pulmonary metastasis was discovered 6 months postoperatively. The patient received eribulin mesylate and subsequent palliative doxorubicin, and her case was complicated by doxorubicin-induced congestive heart failure. She subsequently developed progressive systemic metastatic disease, including brain and bone involvement, and died of the disease 65 months after initial presentation. CONCLUSIONS This case demonstrates that SS18 FISH confirmation is essential when FNA is non-diagnostic for a thyroid spindle cell mass. Despite negative margins and adjuvant radiation, early pulmonary metastasis and ultimately fatal systemic metastatic disease to the brain and bone occurred, underscoring the aggressive clinical course of PSST. Doxorubicin-induced cardiac toxicity further illustrates the systemic therapy burden. BCL-2-directed strategies remain investigational. Complete surgical resection with negative margins is the cornerstone of management.

PMID 43010634
阅读全文 →
PubMedFrontiers in immunology2026-11-05

Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial.

Lu Haiqi H, Wang Xufei X, Wang Zhuo Z, Chen Miaoqin M et al.

Advanced triple-negative breast cancer (TNBC) has an extremely poor prognosis, and current therapies offer limited benefits for patients with low programmed cell death ligand 1(PD-L1) expression. This study innovatively proposes a "novel chemotherapy + bispecific antibody" model. Eribulin Mesylate (hereinafter referred to as Eribulin), a novel microtubule inhibitor, kills tumor cells while remodeling the tumor microenvironment. When combined with the PD-1/VEGF bispecific antibody Ivonescimab, it concurrently dismantles immunosuppression and angiogenesis to synergistically overcome immunotherapy resistance. This is a multicenter, open-label, single-arm clinical trial designed to enroll 29 patients with locally advanced or metastatic TNBC who have not received prior systemic anticancer therapy, and who are either ineligible for radical surgical resection or local therapy, or have experienced disease progression following postoperative adjuvant therapy. The primary endpoint is the objective response rate (ORR) assessed by Investigator Assessment (INV) at each participating center based on strict adherence to Response Evaluation Criteria in Solid Tumors version 1.1(RECIST v1.1) criteria. Secondary endpoints include progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety. Exploratory endpoints involve potential biomarkers, the correlation between PD-L1 expression and efficacy, and patient-reported outcomes (PROs). This combination regimen is expected to leverage the synergistic advantages of "chemotherapy-promoted immunity and potent bispecific antibody efficacy," providing novel evidence-based medical evidence for the first-line treatment of metastatic TNBC and thereby effectively addressing significant unmet clinical needs. http://www.chictr.org.cn/, identifier ChiCTR2600117652.

PMID 42984708
阅读全文 →
PubMedFrontiers in medicine2026-11-05

Meta-analysis of the effect of nafamostat mesilate versus no-anticoagulation regimens in adult patients undergoing continuous renal replacement therapy.

Wang Yao Y, Du Xiaoli X, Wen Dan D, Xu Rong R et al.

Continuous renal replacement therapy (CRRT) is a critical treatment for critically ill patients with acute kidney injury. However, effective anticoagulation of the extracorporeal circuit remains a clinical challenge. Nafamostat mesilate (NM), a serine protease inhibitor, possesses localized anticoagulation properties; however, its efficacy and safety in high-bleeding-risk populations have not been systematically evaluated. To compare the efficacy and safety of NM anticoagulation and no-anticoagulation regimens in patients undergoing CRRT. Randomized controlled trials (RCTs) and cohort studies were retrieved from PubMed, Web of Science, MEDLINE, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, Wanfang Database, Chinese National Knowledge Infrastructure, and the Chinese Biomedical Literature Database. We included studies on adult patients receiving CRRT where the intervention and control groups were treated with NM anticoagulation and no-anticoagulation regimens, respectively. Primary outcomes included filter lifespan, number of filters used, coagulation indicators, bleeding events, and in-hospital mortality. The meta-analysis was conducted using RevMan 5.4 software. Eight studies involving 969 patients were included. The meta-analysis demonstrated that, compared with the control group, the NM group had a significantly prolonged filter lifespan (P = 0.01) and a reduced number of filters used (P < 0.0001). The activated partial thromboplastin time (P = 0.89), prothrombin time (P = 0.88), and international normalized ratio (P = 0.60) showed no significant differences. Both groups demonstrated clinically similar risks of bleeding events (P = 0.53). However, the NM group demonstrated a significantly reduced in-hospital mortality, compared with the control group (P = 0.02). The NM anticoagulation regimen effectively extended the CRRT filter lifespan, reduced resource consumption, and improved patient survival outcomes without increasing the bleeding risk, demonstrating particular value for high-bleeding-risk populations. Future multicenter RCTs are warranted to validate applicability of NM in non-East Asian populations. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261399024, identifier: PROSPERO CRD420251077578.

PMID 42985103
阅读全文 →

注册免费账户还可查看另外 2324 篇文献

免费注册查看全部文献 →

了解更多eribulin mesilate